Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy

American Journal of Nephrology

Volumn 43, Issue 6, 2016, Pages 397-407

  Cianciolo, Giuseppe ^a,b   Galassi, Andrea ^c   Capelli, Irene ^a,b   Angelini, Maria Laura ^a,b   Manna, Gaetano La ^a,b   Cozzolino, Mario ^d,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c DESIO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic kidney disease mineral and bone disorder; Fibroblast growth factor 23; Parathyroid hormone; Proteinuria; Renal transplant; Vitamin D

Indexed keywords

VITAMIN D;

BONE DISEASE; CARDIOVASCULAR DISEASE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; POST TRANSPLANTATION BONE DISEASE; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL GRAFT DYSFUNCTION; REVIEW; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; DRUG EFFECTS;

CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; VITAMIN D;

EID: 84977646434     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000446863     Document Type: Review

References (89)

1. Wolfe RA, Ashby VB, Milford EL, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Tonelli M, Wiebe N, Knoll G, et al: Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11: 2093-2109.
3. Sellarés J, de Freitas DG, Mengel M, et al: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
4. Weiner DE, Carpenter MA, Levey AS, et al: Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: The FAVORIT trial. Am J Transplant 2012; 12: 2437-2445.
5. Ojo AO, Morales JM, González-Molina M, et al; Scientific Registry of Transplant Recipients and; Spanish Chronic Allograft Study Group: Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant 2013; 28: 213-220.
6. Galassi A, Bellasi A, Papagni S, et al: Which vitamin D in CKD-MBD? The time of burning questions. Biomed Res Int 2013; 2013: 864012.
7. Courbebaisse M, Souberbielle JC, Thervet E: Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 2010; 89: 131-137.
8. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
9. Ormsby RT, Findlay DM, Kogawa M, et al: Analysis of vitamin D metabolism gene expression in human bone: evidence for autocrine control of bone remodelling. J Steroid Biochem Mol Biol 2014; 144: 110-113.
10. Vaidya A, Williams JS: Vitamin D and insulin sensitivity: can gene association and pharmacogenetic studies of the vitamin D receptor provide clarity? Metabolism 2012; 61: 759-761.
11. Gonzalez-Parra E, Rojas-Rivera J, Tuñón J, et al: Vitamin D receptor activation and cardiovascular disease. Nephrol Dial Transplant 2012; 27(suppl 4):iv17-iv21.
12. Thacher TD, Clarke BL: Vitamin D insufficiency. Mayo Clin Proc 2011; 86: 50-60.
13. Bover J, Cozzolino M: Mineral and bone disorders in chronic kidney disease and endstage renal disease patients: new insights into vitamin D receptor activation. Kidney Int Suppl (2011) 2011; 1: 122-129.
14. Li YC, Qiao G, Uskokovic M, et al: Vitamin D: A negative endocrine regulator of the reninangiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90: 387-392.
15. Zhang Z, Sun L, Wang Y, et al: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
16. Tan X, Li Y, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
17. de Borst MH, Hajhosseiny R, Tamez H, et al: Active vitamin D treatment for reduction of residual proteinuria: A systematic review. J Am Soc Nephrol 2013; 24: 1863-1871.
18. Boudville NC, Hodsman AB: Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant 2006; 21: 2621-2624.
19. Querings K, Girndt M, Geisel J, et al: 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 2006; 91: 526-529.
20. Sadlier DM, Magee CC: Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: A prospective study. Clin Transplant 2007; 21: 683-688.
21. Keyzer CA, Riphagen IJ, Joosten MM, et al: Associations of 25(OH) and 1, 25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J Clin Endocrinol Metab 2015; 100: 81-89.
22. Bienaimé F, Girard D, Anglicheau D, et al: Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 2013; 24: 831-841.
23. Barros X, Fuster D, Rodríguez N, et al: Rapid calcitriol increase and persistent calcidiol insufficiency in the first 6 months after kidney transplantation. Nucl Med Commun 2015; 36: 489-493.
24. Douthat WG, Chiurchiu CR, Massari PU: New options for the management of hyperparathyroidism after renal transplantation. World J Transplant 2012; 2: 41-45.
25. Economidou D, Dovas S, Papagianni A, et al: FGF-23 Levels before and after renal transplantation. J Transplant 2009; 2009: 379082.
26. Evenepoel P, Meijers BK, de Jonge H, et al: Recovery of hyperphosphatoninsm and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829-1836.
27. Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, et al: Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Nephrol Dial Transplant 2012; 27: 4227-4235.
28. Mazzaferro S, Pasquali M, Pugliese F, et al: Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: A role for FGF23. J Nephrol 2012; 25: 1108-1118.
29. Dusso AS, Finch J, Brown A, et al: Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72: 157-164.
30. Alshayeb HM, Josephson MA, Sprague SM: CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis 2013; 61: 310-325.
31. Sanchez Fructuoso AI, Maestro ML, Calvo N, et al: Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation. Transplant Proc 2012; 44: 2551-2554.
32. Krajisnik T, Olauson H, Mirza MA, et al: Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010; 78: 1024-1032.
33. Olauson H, Lindberg K, Amin R, et al: Parathyroid-Specific deletion of klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 2013; 9:e1003975.
34. Pascussi JM, Robert A, Nguyen M, et al: Possible involvement of pregnane X receptorenhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115: 177-186.
35. Akeno N, Matsunuma A, Maeda T, et al: Regulation of vitamin D-1alpha-hydroxylase and-24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 2000; 164: 339-348.
36. Neves CL, dos Reis LM, Batista DG, et al: Persistence of bone and mineral disorders 2 years after successful kidney transplantation. Transplantation 2013; 96: 290-296.
37. Bacchetta J, Dubourg L, Harambat J, et al: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010; 95: 1741-1748.
38. Wesseling-Perry K, Tsai EW, Ettenger RB, et al: Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23? Nephrol Dial Transplant 2011; 26: 3779-3784.
39. Filipov JJ, Zlatkov BK, Dimitrov EP, et al: Relationship between vitamin D status and immunosuppressive therapy in kidney transplant recipients. Biotechnol Biotechnol Equip 2015; 29: 331-335.
40. Lee CT, Ng HY, Lien YH, et al: Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol 2011; 34: 87-94.
41. Grenet O, Bobadilla M, Chibout SD, et al: Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem Pharmacol 2000; 59: 267-272.
42. Brandenburg VM, Politt D, Ketteler M, et al: Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 2004; 77: 1566-1571.
43. Kodras K, Haas M: Effect of kidney transplantation on bone. Eur J Clin Invest 2006; 36(suppl 2):63-75.
44. Carlini RG, Rojas E, Weisinger JR, et al: Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000; 36: 160-166.
45. Ball AM, Gillen DL, Sherrard D, Weiss NS, et al: Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: 3014-3018.
46. Brandenburg VM, Westenfeld R, Ketteler M: The fate of bone after renal transplantation. J Nephrol 2004; 17: 190-204.
47. Lehmann G, Ott U, Stein G, et al: Renal osteodystrophy after successful renal transplantation: A histomorphometric analysis in 57 patients. Transplant Proc 2007; 39: 3153-3158.
48. Borchhardt K, Sulzbacher I, Benesch T, et al: Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7: 2515-2521.
49. Perrin P, Caillard S, javier RM, et al: Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 2013; 13: 2653-2663.
50. Giannini S, D'Angelo A, Nobile M, et al: The effects of vitamin D receptor polymorphism on secondary hyperparathyroidism and bone density after renal transplantation. J Bone Miner Res 2002; 17: 1768-1773.
51. Mazzaferro S, Pasquali M, Taggi F, et al: Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009; 4: 685-690.
52. Gwinner W, Suppa S, Mengel M, et al: Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934-1941.
53. Nankivell BJ, Borrows RJ, Fung CL, et al: The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
54. Schwarz A, Mengel M, Gwinner W, et al: Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341-348.
55. Fukunaga J, Yamaai T, Yamachika E, et al: Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. Bone 2004; 34: 425-431.
56. Hirotani H, Tuohy NA, Woo JT, et al: The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264. 7 cells. J Biol Chem 2004; 279: 13984-13992.
57. Westenfeld R, Schlieper G, Wöltje M, et al: Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis-implications for post-transplantation bone disease. Nephrol Dial Transplant 2011; 26: 4115-4123.
58. Giannini S, Sella S, Silva Netto F, et al: Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphism and vitamin D deficiency. J Bone Miner Res 2010; 25: 841-848.
59. Campistol JM, Holt DW, Epstein S, et al; Sirolimus European Renal Transplant Study Group: Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int 2005; 18: 1028-1035.
60. Kahwaji J, Bunnapradist S, Hsu JW, et al: Cause of death with graft function among renal transplant recipients in an integrated healthcare system. Transplantation 2011; 91: 225-230.
61. Marcén R, Jimenez S, Fernandez-Rodriguez A, et al: Are low levels of 25-hydroxyvitamin D a risk factor for cardiovascular diseases or malignancies in renal transplantation? Nephrol Dial Transplant 2012; 27(suppl 4): iv47-iv52.
62. Yilmaz MI, Sonmez A, Saglam M, et al: Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol 2013; 37: 126-134.
63. Obi Y, Hamano T, Ichimaru N, et al: Vitamin D deficiency predicts decline in kidney allograft function: A prospective cohort study. J Clin Endocrinol Metab 2014; 99: 527-535.
64. Lee JR, Dadhania D, August P, et al: Circulating levels of 25-hydroxyvitamin D and acute cellular rejection in kidney allograft recipients. Transplantation 2014; 98: 292-299.
65. Amer H, Cosio FG: Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2490-2492.
66. Astor BC, Matsushita K, Gansevoort RT, et al: Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340.
67. Gansevoort RT, Matsushita K, van der Velde M, et al: Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80: 93-104.
68. Ruggenenti P, Perna A, Mosconi L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. 'Gruppo Italiano di Studi Epidemiologici in Nefrologia' (GISEN). Kidney Int 1998; 53: 1209-1216.
69. Shamseddin MK, Knoll GA: Posttransplantation proteinuria: An approach to diagnosis and management. Clin J Am Soc Nephrol 2011; 6: 1786-1793.
70. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 113:S1-S130.
71. Courbebaisse M, Xu-Dubois YC, Thervet E, et al: Cholecalciferol supplementation does not protect against renal allograft structural and functional deterioration: A retrospective study. Transplantation 2011; 91: 207-212.
72. Courbebaisse M, Alberti C, Colas S, et al: Vitamin D supplementation in renal transplant recipients (VITALE): A prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100, 000 UI compared with a dose of 12, 000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial. Trials 2014; 15: 430.
73. Thiem U, Heinze G, Segel R, et al: VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the post-transplant outcome. Trials 2009; 10: 36.
74. Gonzalez E, Rojas-Rivera J, Polanco N, et al: Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation 2013; 95:e49-e52.
75. Trillini M, Cortinovis M, Ruggenenti P, et al: Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 2015; 26: 1205-1214.
76. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, et al: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010; 376: 1543-1551.
77. Agarwal R, Hynson JE, Hecht TJ, et al: Shortterm vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int 2011; 80: 1073-1079.
78. Amer H, Griffin MD, Stegall MD, et al: Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant 2013; 13: 1576-1585.
79. KDIGO CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
80. Anderson PH, Lam NN, Turner AG, et al: The pleiotropic effects of vitamin D in bone. J Steroid Biochem Mol Biol 2013; 136: 190-194.
81. Goldsmith DJ, Covic A, Fouque D, et al: Endorsement of the kidney disease improving global outcomes (KDIGO) chronic kidney disease-mineral and bone disorder (CKDMBD) guidelines: A European renal best practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 25: 3823-3831.
82. NICE National Institute for Health and Care Excellence: Chronic Kidney Disease: Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care, 2014.
83. Wissing KM, Broeders N, Moreno-Reyes R, et al: A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005; 79: 108-115.
84. Sahin G, Yasar NS, Sirmagul B, Bal C, Yalcin AU: The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: A prospective study. Ren Fail 2008; 30: 992-999.
85. Courbebaisse M, Thervet E, Souberbielle JC, et al: Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009; 75: 646-651.
86. Steiner RW, Ziegler M, Halasz NA, et al: Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 1993; 56: 843-846.
87. Cueto-Manzano AM, Konel S, Freemont AJ, et al: Effect of 1, 25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000; 35: 227-236.
88. Torres A, García S, Gómez A, et al: Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004; 65: 705-712.
89. Mainra R, Elder GJ: Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol 2010; 5: 117-124.